Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) [Phase 1, Phase 2]

View source ↗

Summary

A randomized, double-blind, placebo-controlled Phase 1/2 study of delandistrogene moxeparvovec (SRP-9001) for Duchenne muscular dystrophy has been completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Delandistrogene moxeparvovec (delandistrogene moxeparvovec)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Muscular Dystrophy, Duchenne | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-09-15